Brief: Veracyte Q2 Revenue USD 90.3 Million Vs. IBES Estimate USD 83.1 Million
08/08/2023 21:05
Aug 08 (Reuters) - Veracyte Q2 net income USD -8.4 million. * Q2 gross margin 62% * outlook FY revenue USD 342-350 million * outlook FY revenue growth 15-18%
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina